Effects of dibutyryl cyclic AMP and forskolin on phospholipid biosynthesis in thrombin-stimulated human platelets.
The influence of forskolin, an adenylate cyclase activator, and of dibutyryl cyclic AMP (Bt2cAMP) on [3H]glycerol incorporation into glycerolipids was investigated in human platelets. It was found that preincubation with 2.5 mM Bt2cAMP produced a 2-4-fold increase in thrombin-induced incorporation into phospholipids compared to platelets activated by thrombin alone. Pretreatment with forskolin, which increased cellular cAMP content, also resulted in an increase in thrombin-stimulated [3H]glycerol incorporation into phospholipids. These findings demonstrate that a rise in platelet cAMP can accentuate thrombin-induced de novo synthesis of phospholipids from [3H]glycerol. Since the content of cellular cAMP was correlated with its ability to inhibit platelet activation monitored by serotonin release, it seems likely that glycerolipid, in particular phospholipid biosynthesis, is involved in controlling platelet activation by thrombin.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D003994:Bucladesine / Q000494:pharmacology*; D005576:Colforsin; D000242:Cyclic AMP / Q000097:blood; D004224:Diterpenes / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010743:Phospholipids / Q000097:blood*; D012701:Serotonin / Q000378:metabolism; D013917:Thrombin / Q000494:pharmacology*
D004224:Diterpenes; D010743:Phospholipids; D005576:Colforsin; D012701:Serotonin; D003994:Bucladesine; D000242:Cyclic AMP; D013917:Thrombin